For carriers who passed hearing screening with heterozygous variants of GJB2 or SLC26A4, it was still recommended to proceed with the follow‐up of hearing to take precautions against delayed‐onset HL. The gene discussed is SLC26A4; the disease is Hodgkins lymphoma.